Previous studies show that selective β2- or β3-AR agonists have great promise for the treatment of obesity owing to their intrinsic capacity to enhance energy expenditure in humans upon both acute and chronic treatments [16,21,[59], [60], [61]]. The gene discussed is ADRB3; the disease is obesity due to melanocortin 4 receptor deficiency.